Bintai Kinden’s partner files trademark for Covid-19 vaccine

KUALA LUMPUR: Bintai Kinden Corporation Bhd’s partner Generex Biotechnology Corporation has filed for a trademark for its li-Key vaccine and patent for its Ii-Key-SARS-CoV-2 vaccine.

In a statement issued on Thursday, Bintai Kinden said the Ii-Key vaccine was designed to be a complete vaccine for the Covid-19.

Save 30% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 9.73/month

Billed as RM 9.73 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.63/month

Billed as RM 103.60 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Bintai Kinden , Covid-19 , vaccine , Generex Biotechnology

Next In Business News
Oil flat as chances of US strike on Iran recedes
Asia shares near record high on AI optimism, dollar up on receding Fed cut bets
Singapore's December exports rise 6.1% y-o-y, weaker than expected
Bursa Malaysia buoyed by improved investor appetite
PNB offers US$300mil secured exchangeable sukuk to strengthen portfolio diversification
IMF's growth forecasts to show resilience to global trade shocks, Georgieva says
Trading ideas: Binastra, Kerjaya Prospek, D&O, Dengkil, SkyGate, NexG, Vestland, Chin Hin, SC Estate Builder, ES Sunlogy, Infomina
Wall St ends higher as banks gain on upbeat results
Oil settles down as Trump comments ease Iranian supply concerns
Property segment set for solid expansion

Trending in Business

Others Also Read

Load more

Copyright © 1995- Star Media Group Berhad [197101000523 (10894-D)]

Best viewed on Chrome browsers.